BioCatalystWatch
IMAWorkspace / IMA / OverviewCompany library
Price
Market cap
Next catalystExpected Q4 2027olevaprubart — ADAPTIVE · Phase 2 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

olevaprubart

OX40

PreINDP1P2P3FilingApproved
Upcoming / outlook

olevaprubart

OX40

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

olevaprubart

OX40

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

olevaprubart

OX40

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

olevaprubart

OX40

PreINDP1P2P3FilingApproved
IMG-004

BTK

PreINDP1P2P3FilingApproved

Partner / License out

ILT7

History / paused

olevaprubart

OX40

PreINDP1P2P3FilingApproved

IL-36R

IL-36R

IL-36R

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

IMA PR & News

PR & News

IMA SEC archive